腺苷、利多卡因与镁对储存血小板功能增强作用的评价
该研究在体外将腺苷、利多卡因、镁(ALM)及其单组分或组合直接加入血小板小袋,分别在22°C或4°C的100%血浆和血小板添加液中储存至基线、第5天、第10天和第15天检测。血气、细胞分析和流式细胞术仅显示第5天起温度组间差异(p<0.05),治疗组间无差异。对胶原(仅腺苷、仅镁、高剂量ALM)和凝血酶受体激活肽(腺苷+镁、高剂量ALM)的聚集反应在第5天显著高于相应4°C(100%血浆)对照(p<0.05)。血栓弹力图显示4°C 100%血浆储存样本第15天所有指标(反应时间、最大振幅、角度)较室温显著保留(p<0.05),但ALM组与对照间无差异。
要点
- 体外实验中,仅腺苷、仅镁和高剂量ALM在第5天对胶原的聚集反应显著高于相应4°C(100%血浆)对照(p<0.05)。
- 腺苷+镁和高剂量ALM在第5天对凝血酶受体激活肽的聚集反应显著高于相应4°C(100%血浆)对照(p<0.05)。
- 血气、细胞分析及流式细胞术仅见第5天起温度组间差异(p<0.05),治疗组间无差异。
- 血栓弹力图第15天4°C 100%血浆储存样本所有指标较室温显著保留(p<0.05),ALM组与对照无差异。
- 与4°C储存的血小板添加液血小板相比,未见ALM带来的改善。
适用人群与场景
- 体外储存的血小板制品,在100%血浆或血小板添加液中于22°C(室温)或4°C储存至基线、第5天、第10天和第15天。
处置流程与药物剂量
- 腺苷、利多卡因、镁(ALM)处理或其单组分(腺苷、利多卡因、镁或组合)在基线时直接加入血小板小袋用于储存。
研究设计与关键结果
- 研究为体外血小板储存实验,检测时间点为基线、第5天、第10天和第15天,储存温度为22°C或4°C,介质为100%血浆和血小板添加液。
- 血气、细胞分析及流式细胞术仅显示第5天起温度组间差异(p<0.05),治疗组间无差异。
- 对胶原的聚集反应:仅腺苷、仅镁和高剂量ALM在第5天显著高于相应4°C(100%血浆)对照(p<0.05)。
- 对凝血酶受体激活肽的聚集反应:腺苷+镁和高剂量ALM在第5天显著高于相应4°C(100%血浆)对照(p<0.05)。
- 血栓弹力图:第15天4°C 100%血浆储存样本在对照(无ALM)和ALM处理组中所有指标(反应时间、最大振幅、角度)均较室温显著保留(p<0.05),ALM组与对照组间无差异。
- 与4°C储存的血小板添加液血小板相比,未见改善。
证据类型、等级与局限
- 证据类型:体外研究。
- 证据等级:治疗/护理管理,II级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为ALM保护作用的机制仍不明确,可能需要关键细胞功能才能提供保护。
- 本研究中,与4°C储存的血浆样本相比可见胶原和凝血酶受体激活肽聚集的改善,但与4°C储存的血小板添加液血小板相比未见改善。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The combination of adenosine, lidocaine, and magnesium (Mg2+) (ALM) has demonstrated cardioprotective and resuscitative properties in models of cardiac arrest and hemorrhagic shock that are linked to reduction of metabolic demand. Platelets play a key role in resuscitation strategies for ATC but suffer from loss of function following storage in part owing to mitochondrial exhaustion. This study evaluates whether ALM also demonstrates protective properties in stored platelet preparations.
METHODS: Platelets were tested at (baseline, Day 5, Day 10, and Day 15) at 22°C (room temperature) or 4°C in 100% plasma and platelet additive solution. Adenosine, lidocaine, and magnesium treatment or its individual components (A, L, M, or combinations) were added directly to the minibags at baseline for storage. Measurements consisted of blood gas and chemistry analyses, thromboelastography, impedance aggregometry, and flow cytometry.
RESULTS: Blood gas and cell analysis, as well as flow cytometry measures, demonstrated only differences between temperature groups starting at Day 5 (p < 0.05) and no differences between treatment groups. Aggregation response to collagen (A only, M only, and ALM high dose) and thrombin receptor activation peptide (A + M, and ALM high dose) was significantly greater at Day 5 compared to respective 4°C (100% plasma) controls (p < 0.05). Thromboelastography analysis revealed significant preservation of all measures (reaction time, maximum amplitude, and angle) at Day 15 for 4°C-stored samples in 100% plasma in both controls (no ALM) and ALM treatment compared to room temperature (p < 0.05); no differences were observed between the ALM and control groups.
CONCLUSIONS: The mechanism of ALM's protective effect remains unclear; key cellular functions may be required to provide protection. In this study, improvements in collagen and thrombin receptor activation peptide aggregation were seen when compared to 4°C-stored plasma samples although no improvements were seen when compared to 4°C-stored platelet additive solution platelets.
LEVEL OF EVIDENCE: Therapeutic/care management, level II.
参考来源
- Bynum JA, Taylor AS, Peltier GC, et al. Evaluation of adenosine, lidocaine, and magnesium for enhancement of platelet function during storage. J Trauma Acute Care Surg. 2017. PMID: 28383470. doi:10.1097/TA.0000000000001479
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。